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Abstract To assess the incidence and clinical signifi-
cance as well as predictors of in-stent restenosis (ISR) after
carotid artery stenting (CAS) diagnosed with serial duplex
sonography investigations. We analyzed 215 CAS proce-
dures that had clinical and serial carotid duplex ultrasound
investigations. The incidence of in-stent restenosis (ISR)
and periprocedural as well as long-term clinical compli-
cations were recorded. The influence of an ISR on clinical
complication was analyzed using Kaplan-Meier curves and
clinical risk factors for the development of an ISR with
multivariate logistic regression. During a median follow-up
time of 33.4 months (interquartile range 15.3–53.7) an ISR
of C70% was detected in 12 (6.1%) of 215 arteries (mean
age of 68.1 ± 9.8 years, 71.6% male). The combined
stroke and death rate during long-term follow-up was sig-
nificantly higher in the group with an ISR [odds ratio (OR):
3.59, 95% confidence interval (CI): 1.50–8.59, p = 0.004].
After applying multivariate logistic regression analysis
contralateral carotid occlusion (OR 10.11, 95% CI
2.06–49.63, p = 0.004), carotid endarterectomy (CEA)
restenosis (OR 8.87, 95% CI 1.68–46.84, p = 0.010) and
postprocedural carotid duplex ultrasound with a PSV
C120 cm/s (OR 6.33, 95% CI 1.27–31.44, p = 0.024)
were independent predictors of ISR. ISR after CAS during
long-term follow-up is associated with a higher proportion
of clinical complications. A close follow-up is suggested
especially in those patients with the aforementioned inde-
pendent predictors of an ISR. Against the background of a
lacking established treatment of ISR, these findings should
be taken into account when offering CAS as a treatment
alternative to CEA.
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Introduction
Atherosclerotic stenosis of the carotid artery is known as a
major risk factor for ischaemic stroke. Carotid endarter-
ectomy (CEA) in combination with best medical treatment
of cerebrovascular risk factors is considered to be the gold
standard for primary and secondary stroke prevention in
patients with significant carotid artery stenosis. More
recently, carotid angioplasty and stenting (CAS) have
emerged as a potentially less invasive treatment alternative.
However, the results of randomized controlled studies and
subsequent meta-analyses comparing CEA with CAS failed
to prove a general superiority of CAS [1–3]. Nevertheless,
there is growing evidence that a subgroup of patients aged
\70 years may benefit from CAS intervention [3, 4]. A
current major drawback is that prospective data with
respect to the clinical long-term outcome are sparse and
controversially discussed [1]. Especially the occurrence of
an in-stent restenosis (ISR) could endanger the long-term
efficacy and safety of CAS. Considering the fact that to
date there is no established treatment strategy for an ISR,
this issue will be of high clinical importance particularly if
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patients \70 years are preferably being treated with CAS
in the future. By now, the exact rate and clinical impact of
ISR during long-term follow-up is still unclear, which may
in part be attributable to different definitions of the duplex
criteria of an ISR during follow-up investigations [5, 6].
Therefore, the current study had three major aims: first,
to investigate the incidence of ISR as assessed with serial
duplex ultrasonography; second, to evaluate the impact of
ISR on clinical complications (stroke or death) during
long-term follow-up; third, to analyze clinical predictors
for ISR in order to identify patients at greatest risk who are
expected to benefit from a rigorous follow-up.
Methods
Patients
Within a prospectively created single-center CAS database
we conducted a retrospective analysis of a total of 198
patients (215 arteries) that had been treated between May
2003 and June 2010. Patients had undergone a CAS
intervention because of a high-grade carotid stenosis
defined as C70% in symptomatic patients and C90% in
asymptomatic patients according to the European Carotid
Surgery Trial (ECST) criteria. A carotid stenosis was
considered symptomatic if the patient had experienced a
transient or permanent ipsilateral ocular or cerebral ische-
mic event within the past 6 months. All patients received
information about the different treatment modalities (CEA,
CAS and best medical treatment) and their respective
advantages and disadvantages, in particularly the potential
complications and risks. With respect to the CAS proce-
dure, all patients were informed about the investigational
nature of CAS and gave their written informed consent.
The current study is in accordance with International
Conference on Harmonisation/Good Clinical Practice
guidelines and was approved by the local ethics committee.
Data collection
An experienced stroke neurologist documented clinical
data potentially responsible for influencing the occurrence
of an ISR at every follow-up visit. The etiology of all
stenoses was atherosclerotic and was further subdivided
into a naı¨ve carotid stenosis or a post-endarterectomy ste-
nosis (CEA restenosis). The following cerebrovascular risk
factors were recorded using history or direct measure-
ments: hypertension (blood pressure C140/90 mmHg
measured on repeated occasions or presence of antihyper-
tensive drugs), hyperlipidemia (fasting serum cholesterol
levels C200 mg/dl or statin therapy), diabetes mellitus
(HbA1c C6.5%, fasting blood glucose C120 mg/dl or
presence of antidiabetic drugs), smoking (current or within
the previous year), coronary artery disease (history of
angina, myocardial infarction, percutaneous transluminal
angioplasty or surgery), peripheral occlusive arterial dis-
ease (history of typical clinical presentation, percutaneous
transluminal angioplasty or surgery) and the presence of
contralateral carotid disease (as assessed with ultrasound
and subdivided into a stenosis C70% or occlusion).
The periprocedural 30-day complications were recorded
and categorized as stroke (any neurological deficit persis-
tent [24 h) or death (death of any cause). Long-term fol-
low-up complications recorded in the current study were
ipsilateral (symptoms corresponding to the treated artery)
stroke or death from any cause. Furthermore, the date and
character of carotid re-interventions (balloon angioplasty
alone, CAS or CEA) and their specific complications (any
stroke or death within 30 days of the procedure) were
registered.
CAS procedure
CAS was carried out by experienced interventional neu-
roradiologists and done under anesthesiological stand-by.
All interventions were performed via a transfemoral
approach. Stent type and the use of filter-based neuropro-
tection devices were chosen at the discretion of the inter-
ventionalist. Only patients scheduled for elective CAS
were recorded; patients in unstable clinical conditions or
with stroke in evolution were excluded. All patients
received orally administered acetylsalicylic acid (100 mg/
day) and clopidogrel (75 mg/day) at least 3 days before the
procedure. Clopidogrel was continued for a minimum of
6 weeks after CAS, and aspirin was administered indefi-
nitely. After being routinely monitored in our intensive
care or stroke unit overnight for at least 1 day, all patients
were discharged afterwards to a normal ward or home. A
clinical examination and duplex sonography were per-
formed before discharge to obtain the clinical status of the
patient and confirm stent patency.
Doppler and duplex sonography
The diagnosis of a carotid artery stenosis and an ISR in
particular was made by carotid duplex ultrasound imaging
using a combination of direct and indirect criteria, and the
presence and extent of intrastenotic and poststenotic tur-
bulent flow. In detail, as direct criteria for the local degree
of stenosis, the peak systolic flow velocities (PSV) within
the stenosis and poststenotic internal carotid artery, the end
diastolic flow velocity in the stenosis, the internal carotid
artery/common carotid artery PSV ratio, and the preste-
notic and poststenotic frequency patterns were determined.
The residual vessel lumen in the B image and the color-
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coded residual vessel area were documented whenever
possible. The flow characteristics of the supratrochlear
artery and the anterior cerebral artery as well as the pul-
satility of the ipsilateral common carotid artery were taken
into account as indirect criteria for a higher grade stenosis.
As one of the main criteria the degree of carotid stenosis at
baseline was graded according to angle-corrected maxi-
mum intrastenotic peak systolic velocities according to
ECST criteria as follows: baseline stenosis C70% = PSV
C200 cm/s, baseline stenosis C80% = PSV C300 cm/s,
baseline stenosis C90% = PSV C400 cm/s.
As there is a lack of generally valid ultrasound criteria
for the definition of an ISR and the current literature sup-
poses different criteria [5, 6], we used locally adopted
criteria with a PSV C300 cm/s as a key feature repre-
senting an ISR of C70%.
All examinations were performed according to a stan-
dardized protocol in the same vascular laboratory with the
same ultrasound equipment (Acuson SequoiaTM 512, Sie-
mens, San Jose´, CA) under the supervision of an experi-
enced, board-certified vascular neurologist (K.G.).
Follow-up protocol
All patients were summoned for serial duplex sonography
follow-up at the hospital’s outpatient clinic at 3, 6 and
12 months after the CAS procedure and every 6 months
thereafter. During these routine postinterventional visits, a
neurologist experienced in neurovascular diseases exam-
ined each patient and recorded the aforementioned clinical
complications.
Statistical analysis
Nominal variables were expressed as count and percent-
ages, continuous values as mean ± standard deviation
(SD) and not normally distributed values as median values
with the corresponding interquartile range (IQR), respec-
tively. For univariate comparisons of categorical data, two-
tailed chi-square statistics with Yates’ correction and uni-
variate Fisher’s exact test were used. The Fisher’s exact
test was applied when the predicted contingency table cell
values were less than 5. Non-normally distributed variables
were compared using a Mann-Whitney U test.
Overall survival Kaplan-Meier curves were obtained
using periprocedural (B30 days) stroke and death as well
as ipsilateral stroke and death during long-term follow-up
([30 days) as a combined endpoint. Interaction for the
occurrence of an ISR was tested using the Mantel-Cox test.
In order to estimate a potential effect of a variable on the
occurrence of an ISR during follow-up, we used a multiple
binominal regression analysis. All variables with a p \ 0.1
on the univariate level were included into a multiple
binominal regression analysis (p to enter = 0.05, p to
leave = 0.1). A two-sided p value of less than 0.05 was
considered to indicate a statistically significant difference.
All statistical analyses were performed with SPSS (version
17, SPSS Inc., Chicago, IL).
Results
Patient characteristics
Two hundred nineteen patients (237 arteries) undergoing
elective carotid artery stenting between May 2003 and June
2010 were analyzed. The data of 21 patients (22 arteries)
had to be excluded because of a missing Duplex follow-up,
yielding a total follow-up rate of 90.7%. Complete clinical
follow-up data with a median duration of 33.4 months
(IQR 15.0–53.7) were available for all the remaining 215
arteries (mean age of 68.1 ± 9.8 years, 71.6% male).
The detailed patient characteristics are given in Table 1.
An ISR C70% with a PSV C300 cm/s was detected in
12/215 (5.6%) arteries in 198 patients after a median of
8.6 months (IQR 3.4–17.3). In 9/12 patients (75%) a ret-
rograde flow of the ipsilateral supratrochlear artery and/or
the anterior cerebral artery could be detected as indirect
duplex criteria of a high grade ISR. Contrast-enhanced
reference imaging was performed in 10/12 cases (83.3%).
A higher grade ISR could be confirmed in 9/10 patients
(90%, 7 by digital subtraction angiography and 2 by
computer tomography angiography).
Considering the development of an ISR, the cardiovas-
cular risk factors hyperlipidemia and peripheral artery
occlusion disease as well as an intervention because of a
CEA restenosis in comparison to a naı¨ve CAS procedure
were statistically significantly more frequent in this group
on univariate level (91.7 vs. 65.0%, p = 0.07; 41.7 vs.
18.2%, p = 0.061; 33.3 vs. 7.4%, p = 0.014, respectively).
Moreover, patients with an ISR during follow-up more
often presented with a contralateral occlusion or stenosis of
the ICA C70% at the time of CAS and a post-interven-
tional flow acceleration with a PSV C120 cm/s (41.7 vs.
11.3%, p = 0.01; 58.3 vs. 24.6%, p = 0.02; 33.3 vs. 5.9%,
p \ 0.001).
Clinical complications
During the 30-day periprocedural follow-up time, the
overall stroke and death rate was 7.4%. Twelve patients
(5.6%) suffered from stroke and five patients (2.3%) died
after a median of 3 days (IQR 3–14). One patient had
discontinued his antithrombotic medication and subse-
quently died of a major stroke after developing an acute in-
stent thrombosis. One patient died of an intracerebral
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hemorrhage immediately after CAS. Other causes of death
were a traumatic subarachnoid hemorrhage after discharge,
a hypopharynx carcinoma, and one patient died of
unknown cause. The combined periprocedural stroke and
death rate was 6.9% in patients without and 16.7% in those
with ISR (p = 0.22).
During the long-term follow-up period ([30 days after
CAS), the combined rate of ipsilateral stroke and death was
10.8% in the subgroup without ISR (7 strokes, 1 stroke
followed by subsequent death and 14 deaths) and 33.3% in
the group with an ISR C70% (2 strokes and 2 deaths;
p = 0.043) after a median of 31.9 months follow-up time
(IQR 16.1–43.3). The cumulative rate of stroke-free sur-
vival for patients with and without ISR C70% is shown in
Fig. 1. Within the patients with ISR there was a statistically
significantly higher risk for clinical complications (ipsi-
lateral stroke and death) during follow-up [odds ratio (OR):
3.59, 95% confidence interval (CI): 1.50–8.59, p = 0.004].
For the whole study group Kaplan-Meier analysis estimates
the freedom of a C70% ISR of 96, 95, 94, 93 and 91% after
each year.
Within the patients with a restenosis the number of
ipsilateral re-interventions during follow-up was
Table 1 Baseline
characteristics of the study
population
* Factors included in multiple
regression analysis (p \ 0.1
univariate analysis)




No ISR ISR C70% p value
N 203 12
Age (years) 68.1 ± 9.8 67.8 ± 6.6 0.928
Male sex 147 (72.4%) 7 (58.3%) 0.328
Weight (kg) 79.4 ± 13.4 82.5 ± 6.6 0.661
Height (m) 170.6 ± 7.6 169.5 ± 3.9 0.782
Left side 115 (56.7%) 4 (33.3%) 0.141
Symptomatic carotid stenosis 154 (75.9%) 7 (58.3%) 0.328
Stroke 94 (46.3%) 3 (25.0%) 0.232
Hemispherical TIA 45 (22.2%) 3 (25.0%) 0.733
Amaurosis fugax 8 (3.9%) 1 (8.3%) 0.410
Hypertension 184 (90.6%) 12 (100%) 0.606
Hyperlipidemia 132 (65.0%) 11 (91.7%) 0.065*
Diabetes 61 (30.0%) 2 (16.7%) 0.516
Tobacco use 59 (29.1%) 5 (41.7%) 0.347
Coronary artery disease 60 (29.6%) 4 (33.3%) 0.753
Peripheral occlusive arterial disease 37 (18.2%) 5 (41.7%) 0.061*
CEA restenosis 15 (7.4%) 4 (33.3%) 0.014*,
Contralateral ICA occlusion 23 (11.3%) 5 (41.7%) 0.011*,
Contralateral ICA stenosis C70% 50 (24.6%) 7 (58.3%) 0.017*
Stenosis C90% before CAS 86 (42.4%) 6 (50.0%) 0.603
PSV C120 cm/s after CAS 12 (5.9%) 4 (33.3%) 0.001*,
Any Stroke or death B30 days 14 (6.9%) 2 (16.7%) 0.221
Ipsilateral stroke or death [30 days 22 (10.8%) 4 (33.3%) 0.043
Median follow-up time (month, IQR) 33.4 (15.5–53.9) 20.8 (5.9–41.8) 0.218
Re-interventions 0 (0%) 8 (66.7%) \0.001





















(203 155 124 91 57 38 15 1)
(12 7 6 5 2 0 0 0)
Fig. 1 Kaplan-Meier curve representing the freedom of clinical
complications (periprocedural any stroke or death and ipsilateral
stroke or any death beyond 30 days) patients with (black) and without
(grey) restenosis during follow-up (p = 0.004)
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significantly higher (0 vs. 66.7%, p \ 0.001) as compared
to those without ISR. In the group with ISR C70% an
ipsilateral re-intervention was performed in eight patients
(3 CAS, 4 PTA, 1 bypass; 66.7%), whereas no interven-
tions of the contralateral side were recorded. Despite the
failure of the attempt to recanalize the acute in-stent
thrombosis as reported above and the patient’s death
3 days later of a major stroke, there were no other peri-
procedural complications associated with a re-intervention
recorded.
Carotid stent procedure
A detailed description of the procedure has been described
recently [7]. In the vast majority a Carotid Wallstent
Monorail (n = 179, Boston Scientific Corp., Natick, MA,
USA) was deployed followed by the use of a Zilver
(n = 13; Cook Medical Inc., Bloomington, IN, USA) or
Precise stent (n = 11, Cordis Endovascular, Warren, NJ,
USA). Distal filter-type embolic protection systems were
used in 61 of 215 (28.4%) patients. No differences were
observed among different stent types, open versus closed
cell design or the use of a protection system between the
two groups. There was a higher proportion of post-proce-
dural residual stenosis as assessed with duplex sonography
(PSV C120 cm/s) in the group with subsequent ISR (5.9
vs. 33.3%, p \ 0.001) compared to those without ISR (see
Table 1).
Independent predictors for ISR
To identify independent predictors for an ISR, a multiple
binominal regression analysis was performed including all
variables, which were imbalanced (p \ 0.1 see Table 1)
within the univariate analysis (hyperlipidemia, peripheral
occlusive artery disease, CEA restenosis, contralateral ICA
occlusion/stenosis C70%, residual stenosis after CAS as
detected by PSV C120 cm/s 1–3 days after CAS). The
strongest statistically significant predictor for the devel-
opment of a subsequent ISR after multiple regression
analysis was a contralateral carotid occlusion (OR 10.11,
95% CI 2.06–49.63, p = 0.004), a CEA restenosis (OR
8.87, 95% CI 1.68–46.84, p = 0.010) as an indication for
the elective CAS and a postprocedural carotid duplex
ultrasound with an elevated PSV C120 cm/s indicating a
residual low-grade stenosis (OR 6.33, 95% CI 1.27–31.44,
p = 0.024).
Discussion
Within the current prospective single-center long-term
CAS surveillance we observed significantly more clinical
complications (stroke or death) in patients who developed
an ISR during follow-up compared to those without ISR.
Moreover, a contralateral carotid occlusion, a CAS inter-
vention of a restenosis after CEA and a postprocedural PSV
[120 cm/s on duplex sonography indicating a residual
low-grade stenosis after CAS could be identified to be
independent risk factors for the development of an ISR
during follow-up. Against the background of the clinical
impact of an ISR, we recommend a tight clinical and
ultrasonographic long-term follow-up of patients treated
with CAS, especially in those with the aforementioned
clinical characteristics.
In the past few years, CAS has frequently been used as
an alternative to CEA for the treatment of a carotid artery
stenosis yet randomized controlled trials have recently
failed to prove a clear benefit in favor for a CAS inter-
vention [1–4]. Especially the long-term benefit of a CAS
procedure is currently debated because the CAS data pre-
sented to date have reported concerning results [8, 9].
However, according to the current literature a CAS inter-
vention is thought to be effective in younger patients,
because two meta-analyses comparing the complications of
CAS and CEA showed a trend towards a favorable out-
come in patients aged \70 years for those patients treated
with CAS [1, 4]. On the other hand, within the recently
published long-term results of the SPACE and EVA-3S
trials, the incidence of an ISR after 2 years diagnosed with
duplex sonography was significantly higher after a CAS
intervention compared to CEA (10.7 vs. 4.6%, p = 0.009
and 12.5 vs. 5.0%; p = 0.02) [8, 10]. In those trials the
higher incidence of ISR during follow-up was not found to
have an impact on clinical complication rates. Therefore, it
has been postulated that restenosis might be a relatively
benign pathology [9]. In contrast, our results support the
notion that the occurrence of ISR among other factors
could endanger the long-term efficacy and safety of CAS,
because the long-term risks for stroke or death were sig-
nificantly higher in patients with an ISR. Against the
background that a CAS intervention might be beneficial
especially in younger patients, these results should be taken
into account for the patient’s individual treatment advice.
One reason for the higher incidence of clinical compli-
cations during medium-term follow-up within our single-
center experience might be the less well-controlled car-
diovascular risk factors after hospital discharge, with, e.g.,
the lack of routinely scheduled blood samples to adjust
current medication such as statins or antidiabetic drugs in
our outpatient clinic. The current setting may however
reflect common everyday practice in real life and might
therefore not necessarily be comparable to the well-struc-
tured settings of randomized controlled trials [3, 4, 8].
Moreover, the positive patient selection favoring the
compliant and well-educated ones in randomized
1900 J Neurol (2012) 259:1896–1902
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controlled trials has to be taken into account and could
explain the disparity in stroke and ISR rates.
As could be expected, the number of re-interventions (8/
12; 66.7%) was higher within the patients with high-grade
restenosis in our study. Although no clinical periprocedural
complications occurred during routinely scheduled re-
interventions within the aforementioned patients, the vari-
ety of different treatment strategies selected to engage the
ISR (3 re-CAS, 4 PTA and 1 bypass surgery) reflects the
fact that an overall accepted treatment strategy for ISR has
not yet been established. As within our series, surgical
treatment of ISR remained an exception in the reviewed
literature because it is technically demanding and can be
associated with periprocedural complications [11]. Cur-
rently, in most of the cases a PTA or re-CAS is performed
[12]. This further highlights the clinical importance of
identifying independent risk factors to be able to detect
those patients during clinical routine and leading to a
thorough long-term sonographic follow-up.
Current data suggest that ISR frequently occurs during
the first year of follow-up [5], which is corroborated within
the current patient cohort: ISR was observed after a median
follow-up of 8.6 months (IQR 3.4–17.3). Not surprisingly,
an insufficient result after CAS with elevated PSV
[120 cm/s within the stent as detected with duplex ultra-
sound was found to be associated with subsequent ISR.
This is in line with previous studies and may be due to
heavily calcified plaques, which made it difficult to
establish an appropriate stent positioning without residual
narrowing [13, 14]. Interestingly, in a study with 563
patients, Randall et al. found that a residual stenosis of
[50% after CAS is associated with an increased risk of
ipsilateral stroke in the long run [15]. Therefore, pursuing
an optimal stent deployment during CAS seems to be a
worthwhile aim, although it is known that an aggressive
postdilation bears the risk of distal embolization. It could
also result in microvascular injury, which may contribute to
an aggravation of inflammatory processes that finally pro-
mote neointimal hyperplasia and ISR [7, 16].
Currently, CAS is a recommended treatment alternative
for patients with CEA restenosis, because a subsequent
CEA bears a higher periprocedural risk than the initial
operation [17, 18]. However, in line with our current
results, which have identified a previous CEA as an inde-
pendent risk factor for the development of ISR after CAS,
previous authors noted that there may be a higher risk of
developing an ISR after stenting of postendarterectomy
arteries [18–20]. These findings emphasize that patients
with restenosis after CEA and a second CAS intervention
are prone to develop a second restenosis.
Another risk factor for ISR identified in this study is
the presence of a contralateral carotid artery occlusion.
Although higher blood flow velocities in a carotid artery
are a well-known phenomenon in case of a contralateral
carotid occlusion [21], the restenosis could be confirmed
in four of five patients within our patient cohort during
conventional angiography (in one patient a confirmation
was not possible because of imaging artifacts during
contrast-enhanced CT angiography). These imaging
results argue against the possibility that an ISR in these
patients might be based solely on a false-positive ultra-
sound measurement triggered by artificially elevated flow
accelerations caused by the contralateral carotid occlu-
sion. According to the current literature, some authors
state that CAS would be the favorable treatment option in
patients with a contralateral carotid artery occlusion [17,
22], because periprocedural complications may be higher
during CEA [23]. Nevertheless, the possibility of an ele-
vated flow, which might overestimate a possible ISR in
patients with contralateral occlusion, should be kept in
mind by clinicians, and even more so the higher incidence
of ISR when offering CAS as a treatment option to this
patient subgroup.
Despite the strengths of the current study we are well
aware of certain limitations: Because of the retrospective
analysis of the prospectively recorded data an ascertain-
ment bias cannot be ruled out, although [90% of all
patients had been followed up. The lack of generally valid
ultrasound criteria for the detection of ISR [5, 6] may have
led to different rates of ISR, although we adopted our
criteria in accordance to the current literature.
Conclusions
ISR after CAS occurs frequently within the first year of
follow-up and is associated with a higher risk of clinical
complications. Considering that a CAS intervention is
frequently used as an alternative to CEA especially in
patients \70 years, a strict and long-term follow-up is
warranted. Especially patients with the presence of a con-
tralateral carotid artery occlusion treated because of a CEA
restenosis or with an insufficient postprocedural result (PSV
[120 cm/s) are prone to develop an ISR. With respect to
the clinical relevance of an ISR and the lack of a com-
monly accepted treatment strategy, all efforts should be
made to carefully follow-up especially these patient sub-
groups. Duplex sonography with adopted local criteria to
identify ISR should be used as a non-invasive, inexpensive
follow-up modality after CAS.
Conflicts of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
J Neurol (2012) 259:1896–1902 1901
123
References
1. Economopoulos KP, Sergentanis TN, Tsivgoulis G, Mariolis AD,
Stefanadis C (2011) Carotid artery stenting versus carotid end-
arterectomy: a comprehensive meta-analysis of short-term and
long-term outcomes. Stroke 42:687–692
2. Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp
HB, de Borst GJ, Lo TH, Gaines P, Dorman PJ, Macdonald S,
Lyrer PA, Hendriks JM, McCollum C, Nederkoorn PJ, Brown
MM (2010) Carotid artery stenting compared with endarterec-
tomy in patients with symptomatic carotid stenosis (International
Carotid Stenting Study): an interim analysis of a randomised
controlled trial. Lancet 375:985–997
3. Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM,
Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ,
Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE,
Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL,
Silver FL, Mohr JP, Lal BK, Meschia JF (2010) Stenting versus
endarterectomy for treatment of carotid-artery stenosis. N Engl J
Med 363:11–23
4. Bonati LH, Dobson J, Algra A, Branchereau A, Chatellier G,
Fraedrich G, Mali WP, Zeumer H, Brown MM, Mas JL, Ringleb
PA (2010) Short-term outcome after stenting versus endarterec-
tomy for symptomatic carotid stenosis: a preplanned meta-anal-
ysis of individual patient data. Lancet 376:1062–1073
5. Gro¨schel K, Riecker A, Schulz JB, Ernemann U, Kastrup A
(2005) Systematic review of early recurrent stenosis after carotid
angioplasty and stenting. Stroke 36:367–373
6. Nederkoorn PJ, Brown MM (2009) Optimal cut-off criteria for
duplex ultrasound for the diagnosis of restenosis in stented car-
otid arteries: review and protocol for a diagnostic study. BMC
Neurol 9:36
7. Wasser K, Schnaudigel S, Wohlfahrt J, Psychogios MN, Knauth
M, Gro¨schel K (2011) Inflammation and in-stent restenosis: the
role of serum markers and stent characteristics in carotid artery
stenting. PLoS One 6:e22683
8. Arquizan C, Trinquart L, Touboul PJ, Long A, Feasson S, Terriat
B, Gobin-Metteil MP, Guidolin B, Cohen S, Mas JL (2011)
Restenosis is more frequent after carotid stenting than after
endarterectomy: the EVA-3S study. Stroke 42:1015–1020
9. Naylor AR (2008) Stenting versus endarterectomy: the debate
continues. Lancet Neurol 7:862–864
10. Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G,
Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H, Jansen
O (2008) Results of the Stent-Protected Angioplasty versus
Carotid Endarterectomy (SPACE) study to treat symptomatic
stenoses at 2 years: a multinational, prospective, randomised
trial. Lancet Neurol 7:893–902
11. Reichmann BL, van Laanen JH, De Vries JP, Hendriks JM,
Verhagen HJ, Moll FL, de Borst GJ (2011) Carotid
endarterectomy for treatment of in-stent restenosis after carotid
angioplasty and stenting. J Vasc Surg 54:87–92
12. van Haaften AC, Bots ML, Moll FL, de Borst GJ (2010) Ther-
apeutic options for carotid in-stent restenosis: review of the lit-
erature. J Vasc Interv Radiol 21:1471–1477
13. Khan MA, Liu MW, Chio FL, Roubin GS, Iyer SS, Vitek JJ
(2003) Predictors of restenosis after successful carotid artery
stenting. Am J Cardiol 92:895–897
14. Cosottini M, Michelassi MC, Bencivelli W, Lazzarotti G, Pic-
chietti S, Orlandi G, Parenti G, Puglioli M (2010) In stent
restenosis predictors after carotid artery stenting. Stroke Res
Treat. pii:864724.:864724
15. Randall MS, McKevitt FM, Kumar S, Cleveland TJ, Endean K,
Venables GS, Gaines PA (2010) Long-term results of carotid
artery stents to manage symptomatic carotid artery stenosis and
factors that affect outcome. Circ Cardiovasc Interv 3:50–56
16. Clark DJ, Lessio S, O’Donoghue M, Tsalamandris C, Schainfeld
R, Rosenfield K (2006) Mechanisms and predictors of carotid
artery stent restenosis: a serial intravascular ultrasound study.
J Am Coll Cardiol 47:2390–2396
17. Kastrup A, Gro¨schel K (2007) Carotid endarterectomy versus
carotid stenting: an updated review of randomized trials and
subgroup analyses. Acta Chir Belg 107:119–128
18. AbuRahma AF, Abu-Halimah S, Bensenhaver J, Nanjundappa A,
Stone PA, Dean LS, Keiffer T, Emmett M, Tarakji M, AbuRahma
Z (2009) Primary carotid artery stenting versus carotid artery
stenting for postcarotid endarterectomy stenosis. J Vasc Surg
50:1031–1039
19. Setacci C, Pula G, Baldi I, de Donato G, Setacci F, Cappelli A,
Pieraccini M, Cremonesi A, Castriota F, Neri E (2003) Deter-
minants of in-stent restenosis after carotid angioplasty: a case-
control study. J Endovasc Ther 10:1031–1038
20. Zhou W, Lin PH, Bush RL, Peden EK, Guerrero MA, Kougias P,
Lumsden AB (2006) Management of in-sent restenosis after
carotid artery stenting in high-risk patients. J Vasc Surg
43:305–312
21. Busuttil SJ, Franklin DP, Youkey JR, Elmore JR (1996) Carotid
duplex overestimation of stenosis due to severe contralateral
disease. Am J Surg 172:144–147 (discussion 147–148)
22. Hobson RW, Mackey WC, Ascher E, Murad MH, Calligaro KD,
Comerota AJ, Montori VM, Eskandari MK, Massop DW, Bush
RL, Lal BK, Perler BA (2008) Management of atherosclerotic
carotid artery disease: clinical practice guidelines of the Society
for Vascular Surgery. J Vasc Surg 48:480–486
23. Gasecki AP, Eliasziw M, Ferguson GG, Hachinski V, Barnett HJ
(1995) Long-term prognosis and effect of endarterectomy in
patients with symptomatic severe carotid stenosis and contralat-
eral carotid stenosis or occlusion: results from NASCET. North
American Symptomatic Carotid Endarterectomy Trial (NAS-
CET) Group. J Neurosurg 83:778–782
1902 J Neurol (2012) 259:1896–1902
123
